Communiqués NextCure, Inc.

Actions

NXTC

US65343E2072

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
5,090 ^USD	+2,62%		+0,20%	-64,13%

03/09	NextCure conclut un neuvième avenant à son contrat de bail et libère ses locaux au 8000 Virginia Manor Road	CI
12/08	Avere, filiale de RTW Biotech, s'introduit en bourse aux États-Unis via une fusion inversée avec NextCure	AN

Communiqués

11/08	Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001	AQ
06/08	NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results	AQ
15/07	Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts	AQ
14/07	NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders	BU
14/07	NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy	AQ
04/06	NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers	AQ
01/06	NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026	AQ
08/05	NextCure : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	NextCure Provides Business Update and Reports First Quarter 2026 Financial Results	AQ
04/05	NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers	AQ
21/04	NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026	AQ
07/04	NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer	AQ
31/03	NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026	AQ
05/03	NextCure Provides Business Update and Reports Full Year 2025 Financial Results	AQ
23/01	NextCure Provides Business Update	AQ
20/11	NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference	AQ
17/11	NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts	AQ
12/11	NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules	AQ
05/11	NextCure : November 2025 Corporate Presentation	PU
05/11	NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results	AQ
16/10/25	NextCure : October 2025 Corporate Presentation	PU
04/09/25	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
01/09/25	NextCure : September 2025 Corporate Presentation	PU
07/08/25	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results	AQ
24/07/25	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta	AQ